日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients

罗沙司他（FG-4592）：用于治疗新发透析患者的贫血

期刊:Journal of the American Society of Nephrology
影响因子:9.4
doi:10.1681/ASN.2015030241
Besarab, Anatole; Chernyavskaya, Elena; Motylev, Igor; Shutov, Evgeny; Kumbar, Lalathaksha M; Gurevich, Konstantin; Chan, Daniel Tak Mao; Leong, Robert; Poole, Lona; Zhong, Ming; Saikali, Khalil G; Franco, Marietta; Hemmerich, Stefan; Yu, Kin-Hung Peony; Neff, Thomas B
贫血
代谢
发表日期：2016
文献求助 收藏

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

口服缺氧诱导因子脯氨酰羟化酶抑制剂罗沙司他（FG-4592）用于治疗慢性肾脏病患者的贫血

期刊:Clinical Journal of the American Society of Nephrology
影响因子:7.1
doi:10.2215/CJN.06890615
Provenzano, Robert; Besarab, Anatole; Sun, Chao H; Diamond, Susan A; Durham, John H; Cangiano, Jose L; Aiello, Joseph R; Novak, James E; Lee, Tyson; Leong, Robert; Roberts, Brian K; Saikali, Khalil G; Hemmerich, Stefan; Szczech, Lynda A; Yu, Kin-Hung Peony; Neff, Thomas B
贫血
代谢
发表日期：2016
文献求助 收藏

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

一项随机、安慰剂对照的罗沙司他（FG-4592）治疗非透析依赖性慢性肾脏病（NDD-CKD）患者贫血的剂量范围和药效学研究

期刊:Nephrology Dialysis Transplantation
影响因子:5.6
doi:10.1093/ndt/gfv302
Besarab, Anatole; Provenzano, Robert; Hertel, Joachim; Zabaneh, Raja; Klaus, Stephen J; Lee, Tyson; Leong, Robert; Hemmerich, Stefan; Yu, Kin-Hung Peony; Neff, Thomas B
贫血
代谢
发表日期：2015
文献求助 收藏